Phaseline

Companies › Taizhou Hanzhong biomedical

Taizhou Hanzhong biomedical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Oct 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Pucotenlimab (HX008)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Metastatic Colorectal CancerOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05652894Pucotenlimab (HX008)Phase 3Metastatic Colorectal CancerOncologyOct 2028

Targets

PDCD1 (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience Johnson & Johnson (Janssen)

Companies built like this

CrystalGenomics SynOx Therapeutics NingBo Junyan Hongshi Biosciences InSightec Agenus

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.